- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.06. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model | 256 | ACCESS Newswire | Insulin Resistance Was Normalized Following 14 Days of Treatment, Supporting Restoration of Glucose Metabolism and Insulin Sensitivity and Further Validating Telomir-Zn's Metal-Homeostasis Mechanism... ► Artikel lesen | |
| 08.06. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.05. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease | 221 | ACCESS Newswire | Study Published in Advances in Redox Research Demonstrated Dose-Dependent Survival Improvement, Reduced Hepatic Copper Burden, Improved Liver Biomarkers, and Reduced Tissue Degeneration in a Preclinical... ► Artikel lesen | |
| 20.05. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 14.05. | Telomir Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 30.04. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer | 313 | ACCESS Newswire | Company Plans to Initiate First-in-Human Phase 1/2 Trial in 1H 2026, Anchored by a Leading U.S. Academic Medical Center. MIAMI, FL / ACCESS Newswire / April 30, 2026 / Telomir Pharmaceuticals, Inc.... ► Artikel lesen | |
| 30.04. | EXCLUSIVE: Telomir Pharmaceuticals Secures FDA Nod For Its Breast Cancer Therapy To Advance Into Human Study | 3 | Benzinga.com | ||
| TELOMIR PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 24.04. | Telomir completes acquisition of TELI Pharmaceuticals | 2 | Investing.com | ||
| 24.04. | Telomir schließt Übernahme von TELI Pharmaceuticals ab und sichert sich globale Rechte an Telomir-1 | 2 | Investing.com Deutsch | ||
| 24.04. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 | 190 | ACCESS Newswire | Transaction establishes global ownership rights of lead program and includes initial capital funding with additional optional milestone-based capital support aligned with key clinical milestones. MIAMI... ► Artikel lesen | |
| 24.04. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.04. | Telomir seeks FDA approval for Telomir-1 to treat breast cancer | 19 | Pharmaceutical Technology | ||
| 31.03. | Telomir reicht IND-Antrag für Krebsmedikamentenkandidaten ein | 1 | Investing.com Deutsch | ||
| 31.03. | Telomir submits IND application for cancer drug candidate | 1 | Investing.com | ||
| 31.03. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 in Advanced and Metastatic Triple-Negative Breast Cancer | 241 | ACCESS Newswire | First-in-class metal-modulating epigenetic therapy targeting iron-dependent pathways with preclinical efficacy and a favorable GLP safety profile. MIAMI, FL / ACCESS Newswire / March 31, 2026 / Telomir... ► Artikel lesen | |
| 31.03. | Telomir Pharmaceuticals beantragt FDA-Zulassung für Brustkrebs-Medikament Telomir-1 | 2 | Investing.com Deutsch | ||
| 27.03. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 17.03. | Telomir Pharmaceuticals, Inc. - 10-K, Annual Report | 4 | SEC Filings | ||
| 17.02. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models | 364 | ACCESS Newswire | Iron-rescue experiments confirm tumor cell mortality is mechanistically driven, not nonspecific cytotoxicity. MIAMI, FL / ACCESS Newswire / February 17, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO)... ► Artikel lesen | |
| 17.02. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,05 | -0,31 % | KI, Onkologie und Rüstung: TeamViewer, BioNTech & Antimony Resources - Ein Mix fürs Portfolio! | Erstellt und veröffentlicht im Auftrag von Antimony Resources Corp. Die Börse ist ein Ort der Extreme und wir blicken heute mit TeamViewer, BioNTech und Antimony Resources auf ein Trio, das aus 3 verschiedenen... ► Artikel lesen | |
| MODERNA | 54,08 | -2,03 % | Moderna-Aktie mit -11% - Einstieg nach der Korrektur? | Die Moderna-Aktie hat nach ihrer beeindruckenden Rallye zuletzt einen Dämpfer hinnehmen müssen und am gestrigen Handelstag rund -11% an Wert verloren. Damit rückt die Aktie nach dem starken Kursanstieg... ► Artikel lesen | |
| VALNEVA | 2,146 | -2,94 % | BRANDMELDUNG bei Valneva: Warum Insider bereits massiv kaufen - So reagieren erfahrene Anleger jetzt | ||
| VIVOSIM LABS | 0,580 | -5,48 % | VivoSim Labs, Inc.: VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027 | SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models... ► Artikel lesen | |
| OCUGEN | 1,186 | -1,33 % | Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa | Cumulative sales milestones up to $255 million and modest upfront/near-term development milestonesRoyalties equaling 22% of net salesOcugen to manufacture and supply OCU400 MALVERN, Pa., July 13,... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,971 | -1,32 % | INOVIO Pharmaceuticals, Inc.: Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China | Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate
ApolloBio's... ► Artikel lesen | |
| VIKING THERAPEUTICS | 32,250 | +1,42 % | Viking Therapeutics to Report Q2 Earnings: What's in Store for the Stock? | ||
| BAVARIAN NORDIC | 24,580 | -1,68 % | Bavarian Nordic A/S: Bavarian Nordic's Chikungunya Vaccine Submitted for Regulatory Approval in Brazil | COPENHAGEN, Denmark, July 13, 2026 - Bavarian Nordic A/S (OMX: BAVA) today announced that its partner, Eurofarma, has submitted a marketing authorization application to the Brazilian Health Regulatory... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,170 | -2,09 % | Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update
Compelling kidney function data and meta-analysis from two Phase 2 studies with varoglutamstat presented... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 15,000 | -0,40 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| GERON | 1,240 | -0,44 % | Geron Corporation: Geron Announces Appointment of Chinmaya Rath as Chief Business Officer | FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer... ► Artikel lesen | |
| IMMUNITYBIO | 6,670 | +2,46 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 0,789 | +3,68 % | CARDIFF ONCOLOGY INC im strukturellen Gleichgewicht | ||
| IMMUNIC | 13,085 | -0,42 % | IMMUNIC, INC. - 8-K, Current Report | ||
| IOVANCE BIOTHERAPEUTICS | 4,345 | +6,76 % | Iovance Biotherapeutics, Inc.: Iovance's Amtagvi (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia | First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma after anti-PD-1 and targeted therapy SAN CARLOS, Calif., June 03, 2026 (GLOBE... ► Artikel lesen |
TELOMIR PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,110 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TELOMIR PHARMACEUTICALS INC finden Sie auf Wallstreet Online.